A breakthrough vaccine can only impact 
human health if it can withstand the 
journey from laboratory to patient. Yet 
cold-chain requirements, distribution 
complexity, and multi-dose regimens con­
tinue to constrain that journey, creating a 
divide between scientific innovation and 
global access.
VitriVax is working toward a future where 
vaccine protection is readily accessible, 
no matter where someone lives.
“Despite decades of advances in vaccine 
science, many of the challenges asso­
ciated with vaccine delivery and access 
remain,” says Romulo Colindres, M.D., 
M.B.A., Chief Executive Officer of Boulder-
based VitriVax. “Our founders recognized 
that if we could solve those delivery and 
stability challenges, we could significantly 
expand the reach and effectiveness of 
many existing and future vaccines.”
At the center of that ambition is ALTA®, 
VitriVax’s proprietary vaccine formu­
lation platform. Instead of reinventing 
the antigen itself, ALTA reimagines how 
vaccines are formulated and delivered. 
By reducing the need for specialized cold 
storage and combining multiple doses 
into a single injection, while producing a 
robust immune response, the technology 
ultimately requires fewer trips to medical 
facilities and less disruption for patients 
and families.
The implications extend well beyond 
convenience. Technologies that make 
vaccines easier to store, transport, and 
administer could expand global immu­
nization while creating more resilient 
systems capable of responding faster to 
future public health emergencies.
Founded in 2014 from technology orig­
inating at CU Boulder, the 54-person 
company has secured a combination of 
venture capital, including its most recent 
Series B financing, and non-dilutive funding 
from the Gates Foundation, Coalition for 
Epidemic Preparedness Innovations, and 
the U.S. Department of Defense. 
And as VitriVax enters its next stage, it 
is choosing to grow at the center of the 
ecosystem where its story began. The 
company recently expanded into 31,465 
square feet at BioMed Realty’s Flatiron 
Park, connecting its team to the infra­
structure, scientific talent, and life sci­
ences community needed to scale.
“Colorado has been more than just a place 
to operate,” Colindres says. “It has been 
an important partner in our journey, 
from university research to a company 
advancing next-generation vaccine tech­
nologies toward the clinic.”
VitriVax is advancing an ALTA Lyme 
disease vaccine today, but its vision 
stretches across multiple vaccine modal­
ities, infectious diseases, and potentially 
therapeutics. The ambition reaches far 
beyond a single product, toward a plat­
form capable of transforming the delivery 
of a generation of medicines.
From Colorado, VitriVax is working toward 
a future in which the reach of a vaccine is 
no longer constrained by geography and 
where the distance between scientific 
innovation and global impact becomes 
dramatically smaller.
VitriVax Expands the Potential of Global Immunization
VitriVax joins other leading life sciences companies and the 
Colorado Quantum Incubator at BioMed Realty’s Flatiron Park.
“
(Colorado) has 
been an important 
partner... from 
university research to 
a company advancing 
next-generation 
vaccine technologies 
toward the clinic.
R O M U LO  CO L I N D R E S,  M . D. ,  M . B. A .
C E O
V I T R I VA X
2026-27 BIOSCIENCE COLORADO     9

View this content as a flipbook by clicking here.